Enanta Pharmaceuticals, Inc. (ENTA)
Nasdaq: ENTA · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2002
Who owns Enanta Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
7
Janus Henderson Group PLC holds 12.1% of Common Stock, as its SCHEDULE 13G filed Nov 7, 2025 says.
Directors and officers
14
report now, of 21 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G · filed Nov 7, 2025 · Common Stock
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Stock, par value $0.01 per share (the "Shares") · 9.9% in Feb 11, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.01 per share (the "Shares")
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Jay R. Luly, Ph.D.
SCHEDULE 13D/A · filed Feb 14, 2025 · Common Stock, par value $0.01 per share
BlackRock Portfolio Management LLC
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock
Krensavage Asset Management, LLC
SCHEDULE 13G · filed Feb 27, 2024 · COMMON STOCK, Par Value $0.01 Per Share
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.01 per share · reported falling below 5%, from 6.78% in Feb 13, 2026
Integrated Core Strategies (US) LLC
SCHEDULE 13G/A · filed Jan 20, 2026 · Common Stock, par value $0.01 per share · reported falling below 5%, from 4.1% in Nov 13, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What ENTA reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Nov 19, 2025.
Insider tradesForm 4
9sales
0purchases
0sales on a scheduled plan
7people selling
$200,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 21 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Luly Jay R. | President and CEO | 1 | $100,000 | 0 | 0 | $0 |
| Trout Harry R. III | Vice President, Finance (Principal Financial Officer) | 2 | $0 | 0 | 0 | $0 |
| Rottinghaus Scott T. | Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 1 | $0 | 0 | 0 | $0 |
| Luu Brendan | Chief Business Officer | 1 | $0 | 0 | 0 | $0 |
| Or Yat Sun | Chief Scientific Officer | 1 | $0 | 0 | 0 | $0 |
| Capps Kathleen S. | Executive Director of Accounting, Controller (Principal Accounting Officer) | 2 | $0 | 0 | 0 | $0 |